NASDAQ:VVUS

VIVUS Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range N/A

50-Day Range

$0.26

▼

$0.47

52-Week Range N/A

Volume2.03 million shs

Average Volume1.44 million shs

Market Capitalization$7.33 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.84

Receive VVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVUS and its competitors with MarketBeat's FREE daily newsletter.

About VIVUS

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.

Enzymes Global Market Report 2021: COVID 19 Growth And Change to 2030 - Yahoo Finance
June 9, 2021 | finance.yahoo.com

Drugs For Erectile Dysfunction Global Market Report 2021: COVID 19 Impact and Recovery to 2030 - Yahoo Finance
May 3, 2021 | finance.yahoo.com

Global Anti-obesity Drugs Market 2021-2025 - Limited Number of Approved Drugs and Use of Bariatric Surgery Limited for Morbid Obesity to Drive Growth - ResearchAndMarkets.com - Business Wire
April 14, 2021 | businesswire.com

DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors - StreetInsider.com
April 3, 2021 | streetinsider.com

DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors - Benzinga
April 3, 2021 | benzinga.com

ViVr Launches. The World's Next Super-App Allows You to Curate All Your Social Channels Into 1 Simple Profile and Reach for The Stars. - StreetInsider.com
March 16, 2021 | streetinsider.com

Icahn Enterprises (IEP) Q4 2020 Earnings Call Transcript - Motley Fool
February 27, 2021 | fool.com

Global $4.7 Billion Erectile Dysfunction Market Outlook and Forecast 2021-2026: Major Players are Eli Lilly and Co, VIVUS, Pfizer, Bayer, Boston Scientific, Coloplast, Teva, Viatris, Dong-A Socio - GlobeNewswire
February 23, 2021 | globenewswire.com

Global Erectile Dysfunction Market Outlook and Forecast Report 2021-2026 - ResearchAndMarkets.com - Business Wire
February 19, 2021 | businesswire.com

Global $5.7 Billion Erectile Dysfunction Drugs Market to 2023 - Forecasts to 2030 - Yahoo Finance
February 16, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:VVUS
Previous Symbol
CUSIP92855110
CIK881524
Webwww.vivus.com
Phone(650) 934-5200
Employees57
Year FoundedN/A

Sales & Book Value

Annual Sales$69.76 million
Price / Sales0.00
Cash FlowN/A
Price / Cash FlowN/A
Book Value($6.50) per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)($2.96)
Net Income$-31,500,000.00
Net Margins-39.28%
Return on EquityN/A
Return on Assets-12.18%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares17,867,000
Market Cap$7.33 million
Next Earnings DateN/A
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.14 out of 5 stars

Medical Sector

567th out of 842 stocks

Pharmaceutical Preparations Industry

250th out of 324 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for VIVUS.

4.3 Community Rank

Outperform Votes
VIVUS has received 377 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
VIVUS has received 219 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
VIVUS has received 63.26% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about VIVUS and other stocks. Vote “Outperform” if you believe VVUS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VVUS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
VIVUS does not currently pay a dividend.
Dividend Growth
VIVUS does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, VIVUS insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.00% of the stock of VIVUS is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 7.32% of the stock of VIVUS is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for VIVUS are expected to grow in the coming year, from ($1.85) to ($1.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of VIVUS is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of VIVUS is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

VIVUS (NASDAQ:VVUS) Frequently Asked Questions

What stocks does MarketBeat like better than VIVUS?

Wall Street analysts have given VIVUS a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but VIVUS wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were VIVUS's earnings last quarter?

VIVUS, Inc. (NASDAQ:VVUS) released its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.80) by $0.31. The biopharmaceutical company earned $19.63 million during the quarter.
View VIVUS's earnings history.

When did VIVUS's stock split? How did VIVUS's stock split work?

Shares of VIVUS reverse split on the morning of Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 10th 2018. An investor that had 100 shares of VIVUS stock prior to the reverse split would have 10 shares after the split.

Who are VIVUS's key executives?

VIVUS's management team includes the following people:

John P. Amos, Chief Executive Officer & Director
Mark K. Oki, Chief Financial & Accounting Officer, Senior VP
Santosh T. Varghese, Chief Medical Officer & Senior Vice President
Ted Broman, Vice President-Chemistry, Manufacturing & Control
Tracy Guo, Vice President-Finance

Who are some of VIVUS's key competitors?

Some companies that are related to VIVUS include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT) and Supernus Pharmaceuticals (SUPN).
View all of VVUS's competitors.

What other stocks do shareholders of VIVUS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VIVUS investors own include Fulcrum Therapeutics (FULC), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), Novavax (NVAX), General Electric (GE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Amarin (AMRN), Geron (GERN) and Idera Pharmaceuticals (IDRA).

What is VIVUS's stock symbol?

VIVUS trades on the NASDAQ under the ticker symbol "VVUS."

How much money does VIVUS make?

VIVUS has a market capitalization of $0.00 and generates $69.76 million in revenue each year. The biopharmaceutical company earns $-31,500,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis.

How many employees does VIVUS have?

VIVUS employs 57 workers across the globe.

What is VIVUS's official website?

The official website for VIVUS is www.vivus.com.

Where are VIVUS's headquarters?

VIVUS is headquartered at 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008.

How can I contact VIVUS?

VIVUS's mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at (650) 934-5200 or via email at [email protected]

This page was last updated on 8/1/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

VIVUS Stock Forecast, Price & News

About VIVUS

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

4.3 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

0.8 Company Ownership

0.6 Earnings and Valuation

VIVUS (NASDAQ:VVUS) Frequently Asked Questions

What stocks does MarketBeat like better than VIVUS?

How were VIVUS's earnings last quarter?

When did VIVUS's stock split? How did VIVUS's stock split work?

Who are VIVUS's key executives?

Who are some of VIVUS's key competitors?

What other stocks do shareholders of VIVUS own?

What is VIVUS's stock symbol?

How much money does VIVUS make?

How many employees does VIVUS have?

What is VIVUS's official website?

Where are VIVUS's headquarters?

How can I contact VIVUS?

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

MarketRank^™

Overall MarketRank^™